MMP2 and neoplasm: The most conclusive evidence of the role of MMP2 in PDAC progression comes from subcutaneous models, in which the injection of shMMP2-silenced PANC1 cells resulted in smaller tumors compared to the injection of control shRNA transduced cells [84], whereas treatment with MMP2-blocking peptides limited tumor growth and angiogenesis [85].